Breaking News Instant updates and real-time market news.

VRTX

Vertex

$87.77

0.43 (0.49%)

, ALIOF

Actelion

$184.01

30.46 (19.84%)

09:52
11/28/16
11/28
09:52
11/28/16
09:52

Vertex, BioMarin rumored as takeover targets, Betaville's Harrington says

In a new interview with Tip TV Finance, Betaville's Ben Harrington discussed rumors that Vertex (VRTX) and BioMarin (BMRN) could be takeover targets. Harrington also discussed rumors regarding Actelion (ALIOF) and the price it may seek from Johnson & Johnson (JNJ). In multiple previous interviews with Tip TV, and once again in his new interview, Harrington discussed rumors that Roche (RHHBY) was considering revisiting a bid for Illumina (ILMN). Reference Link

VRTX

Vertex

$87.77

0.43 (0.49%)

ALIOF

Actelion

$184.01

30.46 (19.84%)

JNJ

Johnson & Johnson

$113.84

-0.2903 (-0.25%)

ILMN

Illumina

$135.19

0.76 (0.57%)

RHHBY

Roche

$28.02

0.6 (2.19%)

BMRN

BioMarin

$89.00

0.9 (1.02%)

  • 29

    Nov

  • 02

    Dec

  • 03

    Dec

  • 07

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

VRTX Vertex
$87.77

0.43 (0.49%)

11/14/16
PIPR
11/14/16
NO CHANGE
PIPR
Piper sees Biotech rally continuing into 2017, lays out five to own
Piper Jaffray analyst Edward Tenthoff expects the rally in Biotechs, following "the trifecta" of a Trump Presidential election, Republican Congress sweep and defeat of Prop 61 in California, to continue into 2017. He recommends focusing on shares of Vertex (VRTX), Regeneron (REGN), Alnylam (ALNY), Exelixis (EXEL) and OncoMed (OMED). Tenthoff has a Neutral rating on Regeneron and Overweight ratings on the other four names.
11/17/16
JANY
11/17/16
INITIATION
JANY
Neutral
Vertex initiated with a Neutral at Janney Capital
11/18/16
JANY
11/18/16
INITIATION
Target $98
JANY
Neutral
Vertex initiated with a Neutral at Janney Capital
Janney Capital analyst Debjit Chattopadhyay initiated Vertex with a Neutral and a $98 price target citing valuation premium.
11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.
ALIOF Actelion
$184.01

30.46 (19.84%)

11/28/16
WELS
11/28/16
NO CHANGE
WELS
Actelion could be acquired for $215 per share, says Wells Fargo
After Johnson & Johnson (JNJ) said that it's in preliminary talks about a deal with Actelion (ALIOF), Wells Fargo estimates that J&J could buy Actelion for $215 per share. The firm thinks that other bidders could emerge for Actelion. It estimates that the deal could be accretive to J&J's EPS by about 5%. Wells keeps an Outperform rating on J&J.
JNJ Johnson & Johnson
$113.84

-0.2903 (-0.25%)

10/19/16
UBSW
10/19/16
NO CHANGE
Target $144
UBSW
Buy
Johnson & Johnson has potential upside from expanding pipeline, says UBS
UBS analyst Matt Miksic noted Johnson & Johnson delivered a solid quarter and said he believes there is upside to his Buy thesis. The analyst cited the company's expanding pipeline, capital allocation strategy, and contracting across its broad portfolio and patient assistance programs is expected to help mitigate pressure from biosimilar competition. Miksic reiterated his Buy rating and raised his price target to $144 from $137 on Johnson & Johnson shares.
10/19/16
LEER
10/19/16
NO CHANGE
Target $140
LEER
Outperform
Johnson & Johnson should be bought on weakness, says Leerink
Leerink analyst Danielle Antalffy believes the recent selloff in Johnson & Johnson's shares was overdone and would recommend buying on weakness. The analyst views the company as well-equipped to manage the inevitable Remicade headwind and continues to believe Johnson & Johnson can drive improving top-line growth in 2017. She reiterates an Outperform rating and $140 price target on the shares.
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Johnson & Johnson should be bought on recent weakness, says RBC Capital
After meeting with J&J's VP, Investor Relations, RBC Capital analyst Glenn Novarro says that the company's Q3 pharma results indicate that the growth of its major drugs can more than offset any declines in Remicade sales next year. The analyst quotes J&J as saying that it has not been using price hikes to increase its sales, and he thinks that the company's diverse business model will allow it to avoid being hurt by any regulatory pressures. He is upbeat on the company's efforts to increase its margins and notes that its medical device results have improved. Novarro keeps a $133 price target and an Outperform rating on the shares.
ILMN Illumina
$135.19

0.76 (0.57%)

10/11/16
10/11/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Comerica (CMA) downgraded to Market Perform from Outperform at FBR Capital with analyst Bob Ramsey citing valuation following the recent strength in the shares. 2. Charter downgraded to Neutral from Buy at MoffettNathanson with analyst Craig Moffett saying shares have risen sharply year-to-date, along with consensus estimates, and views shares as fairly valued. 3. BHP Billiton (BHP) downgraded to Neutral from Buy at UBS with the firm citing its expectations for lower iron ore and coal prices over the next six months. 4. Illumina (ILMN) downgraded to Sell from Neutral at Janney Capital and to Neutral from Buy at Citi. 5. KBR (KBR) downgraded to Sell from Neutral at Goldman with analyst Jerry Revich citing limited growth prospects due to outsized exposure to core LNG and greenfield ammonia capex cycles that are in the early stages of decline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/16
JANY
10/11/16
DOWNGRADE
JANY
Sell
Illumina downgraded to Sell from Neutral at Janney Capital
11/10/16
LEER
11/10/16
INITIATION
Target $145
LEER
Market Perform
Illumina resumed with a Market Perform at Leerink
Leerink analyst Puneet Souda resumed coverage of Illumina with a Market Perform rating and $145 price target.
11/02/16
FANA
11/02/16
DOWNGRADE
Target $116
FANA
Underweight
Illumina downgraded to Underweight from Equal-Weight at First Analysis
First Analysis analyst Joseph Munda downgraded Illumina to Underweight saying the valuation is too high given management's "unconvincing arguments about the outlook," his concerns regarding overcapacity and a "continued lack of new products in the near-term pipeline." The analyst lowered his price target for the shares to $116 from $130 following Illumina's Q3 results.
RHHBY Roche
$28.02

0.6 (2.19%)

11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
10/19/16
LEER
10/19/16
NO CHANGE
LEER
Roche Tecentriq approval increases competition, says Leerink
Leerink analyst Seamus Fernandez says that the FDA approval of Roche's (RHHBY) Tecentriq in second-line non-small cell lung cancer patients regardless of PD-L1 expression comes as no surprise given its previously reported overall survival advantage. Nonetheless, the analyst believes it creates new competition for Bristol-Myers' (BMY) Opdivo and Merck's (MRK) Keytruda in this setting.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
BMRN BioMarin
$89.00

0.9 (1.02%)

11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Biotech stocks should be bought on post-election decline, says RBC Capital
RBC Capital recommends buying biotech stocks today on weakness. The firm notes that stocks usually rebound after they drop due to political events that don't affect their fundamentals, and it believes that the decline in biotech stocks today is in that category. The firm says that President-elect Trump probably won't focus on drug prices or Medicare reform. It adds that biotech companies should benefit from the fact that Congress will stay in GOP hands and the apparent failure of California's Proposition 61 initiative. The firm identifies Celgene (CELG), Biogen (BIIB), Vertex (VRTX), BioMarin (BMRN), and Prothena (PRTA) as its favorite names in the sector.
11/07/16
11/07/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. BioMarin (BMRN) downgraded to Neutral from Overweight at Piper Jaffray with analyst Joshua Schimmer saying he sees a "number of under-appreciated" risks ahead. 2. Akorn (AKRX) downgraded to Underperform from Buy at BofA/Merrill and to Hold from Buy at WallachBeth. 3. GoPro (GPRO) downgraded to Underperform from Neutral at BofA/Merrill. 4. L Brands (LB) downgraded to Underperform from Hold at Jefferies with analyst Randal Konik citing rising competition and pricing competition. 5. Xerox (XRX) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Brian Essex saying both the BPO and DocTech businesses are facing secular pressures and said the Conduent spinco will add $2B of net incremental leverage and faces headwinds in both growth and pricing and will need to focus on margin expansion to drive shareholder value. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, cllick here.
11/07/16
PIPR
11/07/16
UPGRADE
Target $335
PIPR
Overweight
Biogen upgraded to Overweight from Neutral at Piper Jaffray
In a research note partially titled "We Hope We Don't Regret This," Piper Jaffray analyst Joshua Schimmer upgraded Biogen (BIIB) to Overweight with an unchanged price target of $335. The company still has time to "get its act together to maximize the value of its SMA franchise, and stop being M&A disciplined/pipeline-undisciplined," Schimmer tells investors in a research note. He believes the valuation is "reasonable" for the Alzheimer's and SMA franchises as well as some "interesting" pipeline opportunities. Schimmer this morning also downgraded BioMarin (BMRN) to Neutral.

TODAY'S FREE FLY STORIES

QCOM

Qualcomm

$57.22

0.08 (0.14%)

03:55
02/27/17
02/27
03:55
02/27/17
03:55
Conference/Events
Qualcomm to hold an investor session at Mobile World Congress 2017 »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 13

    Mar

03:05
02/27/17
02/27
03:05
02/27/17
03:05
General news
FX Update: The yen has seen a safe haven bid »

FX Update: The yen has…

ERIC

Ericsson

$6.45

-0.08 (-1.23%)

01:55
02/27/17
02/27
01:55
02/27/17
01:55
Conference/Events
Ericsson to hold a media and analyst briefing at Mobile World Congress 2017 »

Media & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 29

    Mar

SSNLF

Samsung

, T

AT&T

$42.36

0.41 (0.98%)

22:24
02/26/17
02/26
22:24
02/26/17
22:24
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

SSNLF

Samsung

T

AT&T

$42.36

0.41 (0.98%)

QCOM

Qualcomm

$57.22

0.08 (0.14%)

INTC

Intel

$36.53

0.35 (0.97%)

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

DBOEY

Deutsche Boerse

$8.60

-0.045 (-0.52%)

CMCSA

Comcast

$37.89

0.24 (0.64%)

CMCSK

Comcast

LGF.A

Lionsgate

$27.18

-0.08 (-0.29%)

LGF.B

Lionsgate

$25.16

-0.19 (-0.75%)

TV

Grupo Televisa

$26.44

0.69 (2.68%)

RIG

Transocean

$13.75

-0.56 (-3.91%)

GPN

Global Payments

$78.97

0.76 (0.97%)

AXTA

Axalta Coating

$29.38

-0.09 (-0.31%)

SNAP

Snap Inc.

HOG

Harley-Davidson

$56.56

-1.12 (-1.94%)

SAM

Boston Beer

$159.20

1.3 (0.82%)

STX

Seagate

$47.75

0.36 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 06

    Mar

  • 13

    Mar

  • 19

    Mar

  • 28

    Mar

  • 04

    Apr

  • 05

    Apr

  • 02

    Mar

NOK

Nokia

$5.14

-0.01 (-0.19%)

, VZ

Verizon

$50.60

0.29 (0.58%)

21:19
02/26/17
02/26
21:19
02/26/17
21:19
Hot Stocks
Nokia CEO: 'Noise' about carrier M&A to heat up in 2017 »

Speaking at a press event…

NOK

Nokia

$5.14

-0.01 (-0.19%)

VZ

Verizon

$50.60

0.29 (0.58%)

T

AT&T

$42.36

0.41 (0.98%)

TMUS

T-Mobile

$62.21

0.14 (0.23%)

S

Sprint

$8.94

-0.02 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 06

    Mar

  • 23

    May

SNE

Sony

$30.93

-0.31 (-0.99%)

20:43
02/26/17
02/26
20:43
02/26/17
20:43
Hot Stocks
Sony confirms 915,000 PlayStation VR global unit sales »

Sony Interactive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Mar

  • 10

    Mar

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

, BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

20:38
02/26/17
02/26
20:38
02/26/17
20:38
Hot Stocks
Berkshire Hathaway says paid roughly $110.17 per share for Apple stake »

Berkshire Hathaway…

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

AAPL

Apple

$136.66

0.13 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 13

    Mar

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

, BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

20:31
02/26/17
02/26
20:31
02/26/17
20:31
Hot Stocks
Buffett: Will be 'ready to act' on share repurchase opportunities »

Writing in Berkshire…

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

20:25
02/26/17
02/26
20:25
02/26/17
20:25
Hot Stocks
Samsung teases March 29 date for next Galaxy device »

Samsung has issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 28

    Mar

SNE

Sony

$30.93

-0.31 (-0.99%)

20:14
02/26/17
02/26
20:14
02/26/17
20:14
Periodicals
Sony sells 915,000 Playstation VR units in first four months, NYT says »

Speaking in a New York…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Mar

  • 10

    Mar

AAPL

Apple

$136.66

0.13 (0.10%)

20:07
02/26/17
02/26
20:07
02/26/17
20:07
Hot Stocks
Al Gore sells 215,400 shares of Apple »

Apple board member and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 13

    Mar

BBRY

BlackBerry

$7.08

-0.08 (-1.12%)

20:00
02/26/17
02/26
20:00
02/26/17
20:00
Hot Stocks
TCL Communication unveils 'BlackBerry KEYone' smartphone »

Smartphone manufacturer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$153.48

0.19 (0.12%)

, GD

General Dynamics

$189.63

1.33 (0.71%)

19:57
02/26/17
02/26
19:57
02/26/17
19:57
Periodicals
Trump to seek 'sharp' boost in defense spending, NYT says »

President Donald Trump…

RTN

Raytheon

$153.48

0.19 (0.12%)

GD

General Dynamics

$189.63

1.33 (0.71%)

LMT

Lockheed Martin

$266.00

1.15 (0.43%)

BA

Boeing

$177.44

0.58 (0.33%)

UTX

United Technologies

$112.46

0.37 (0.33%)

NOC

Northrop Grumman

$245.05

1.19 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMAX

IMAX

$32.75

1.6 (5.14%)

19:52
02/26/17
02/26
19:52
02/26/17
19:52
Hot Stocks
IMAX says China's Bona Film commits to 30 new IMAX theatres »

IMAX and IMAX China…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 06

    Mar

  • 28

    Mar

  • 28

    Mar

F

Ford

$12.47

-0.09 (-0.72%)

, GM

General Motors

$36.90

-0.35 (-0.94%)

19:49
02/26/17
02/26
19:49
02/26/17
19:49
Periodicals
Chao says Trump administration reviewing autonomous car guidance, Reuters says »

Transportation Secretary…

F

Ford

$12.47

-0.09 (-0.72%)

GM

General Motors

$36.90

-0.35 (-0.94%)

TSLA

Tesla

$257.00

1.01 (0.39%)

GOOG

Alphabet

$828.64

-2.69 (-0.32%)

GOOGL

Alphabet Class A

$847.81

-3.19 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 06

    Mar

  • 19

    Mar

INVH

Invitation Homes

$21.60

0.02 (0.09%)

19:35
02/26/17
02/26
19:35
02/26/17
19:35
Initiation
Invitation Homes initiated  »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBF

SoftBank

$75.88

-1 (-1.30%)

19:24
02/26/17
02/26
19:24
02/26/17
19:24
Periodicals
SoftBank poised to invest over $3B in WeWork, CNBC says »

SoftBank is nearing an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRPN

Groupon

$4.47

0.05 (1.13%)

19:22
02/26/17
02/26
19:22
02/26/17
19:22
Recommendations
Groupon analyst commentary  »

Piper believes Groupon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

ALSN

Allison Transmission

$36.79

0.24 (0.66%)

, F

Ford

$12.47

-0.09 (-0.72%)

19:07
02/26/17
02/26
19:07
02/26/17
19:07
Downgrade
Allison Transmission, Ford rating change  »

Allison Transmission…

ALSN

Allison Transmission

$36.79

0.24 (0.66%)

F

Ford

$12.47

-0.09 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 11

    May

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

, BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

18:39
02/26/17
02/26
18:39
02/26/17
18:39
Hot Stocks
Berkshire Hathaway's Buffett: Expect normalized earning power to grow every year »

Writing in Berkshire…

BRK.A

Berkshire Hathaway

$255,040.00

140 (0.05%)

BRK.B

Berkshire Hathaway

$170.22

0.07 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBOEY

Deutsche Boerse

$8.60

-0.045 (-0.52%)

18:26
02/26/17
02/26
18:26
02/26/17
18:26
Hot Stocks
Deutsche Boerse sees European Commission merger decision by end of March »

Deutsche Boerse issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MESO

Mesoblast

$6.40

-0.14 (-2.14%)

18:23
02/26/17
02/26
18:23
02/26/17
18:23
Hot Stocks
Mesoblast outlines expected 2017 milestones »

Mesoblast stated that,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Apr

LIOX

Lionbridge

16:58
02/26/17
02/26
16:58
02/26/17
16:58
Conference/Events
Lionbridge to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSA

Comcast

$37.89

0.24 (0.64%)

, CMCSK

Comcast

16:54
02/26/17
02/26
16:54
02/26/17
16:54
Hot Stocks
Box Office Battle: Comedy horror 'Get Out' thrills in $31M opening »

Comcast's (CMCSA)…

CMCSA

Comcast

$37.89

0.24 (0.64%)

CMCSK

Comcast

TWX

Time Warner

$97.28

0.6225 (0.64%)

LGF.A

Lionsgate

$27.18

-0.08 (-0.29%)

LGF.B

Lionsgate

$25.16

-0.19 (-0.75%)

DIS

Disney

$110.32

0.59 (0.54%)

FOX

21st Century Fox

$30.23

0.23 (0.77%)

FOXA

21st Century Fox

$30.61

0.27 (0.89%)

VIA

Viacom

VIAB

Viacom

$43.89

0.03 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 06

    Mar

WAT

Waters

$156.40

1.51 (0.97%)

16:38
02/26/17
02/26
16:38
02/26/17
16:38
Conference/Events
Waters to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 01

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.